This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Myelofibrosis
MYELOFIBROSIS
primary myelofibrosis: Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of approximately 1 case per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
26 |
4. Check minimum number of eventsNone |
26 |
5. Include endpointsNone |
26 |
6. Filter based on genotype QC (FinnGen only) |
26 |
Control definitions (FinnGen only)
- Control exclude
- MYELOPROF
Extra metadata
- First used in FinnGen datafreeze
- DF2, additional
Similar endpoints
↥List of similar endpoints to
Myelofibrosis
based on the number of shared cases.
Similar with more cases:
- Myeloproliferative diseases (CML excluded)
- Myeloproliferative diseases
- Neoplasms
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1166 | 538 | 578 |
| Only index persons | 125 | 73 | 52 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.00 | 0.00 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 68.79 | 68.12 | 69.58 |
| Only index persons | 44.03 | 44.89 | 42.83 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 26 | 9 | 17 |
| Unadjusted period prevalence (%) | 0.01 | 0.00 | 0.01 |
| Median age at first event (years) | 50.83 | 36.38 | 58.48 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
9
17
7.47
3.93
10.7
1.9
u/l
437.1
269.1
—
9
17
(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
10
31
4.62
3.15
1.6
1.8
mg/l
2.9
3.1
—
10
26
(3002030) Lymphocytes/100 leukocytes in Blood
14
63
3.65
2.59
15.8
4.7
%
24.5
25.1
0.08
14
57
(3018010) Neutrophils/100 leukocytes in Blood
13
62
3.19
2.10
16.1
4.7
%
57.7
59.9
0.28
13
56
(40760892) CBC W Ordered Manual Differential panel - Blood
8
29
3.52
1.99
10.7
3.8
—
—
—
0
0
(3019069) Monocytes/100 leukocytes in Blood
12
62
2.74
1.60
15.8
4.5
%
8.7
8.9
0.10
12
56
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
5
15
3.86
1.60
2.2
1.7
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
5
15
3.86
1.60
1.8
1.7
—
—
—
0
0
(3026493) Urate [Moles/volume] in Serum or Plasma
7
28
3.04
1.58
5.7
2.8
umol/l
34543.1
16445.3
—
7
20
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
11
57
2.61
1.43
8.3
3.6
—
—
—
0
0
(3018677) aPTT in Platelet poor plasma by Coagulation assay
5
17
3.38
1.43
1.8
2.4
s
30.0
29.4
—
5
17
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
5
18
3.18
1.35
2.2
1.8
—
—
—
0
0
(3023368) Bacteria identified in Blood by Culture
8
39
2.51
1.29
2.9
3.8
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
7
34
2.44
1.13
1.6
1.7
—
—
—
0
0
(3021960) Folate [Moles/volume] in Serum or Plasma
7
35
2.36
1.10
2.1
1.7
nmol/l
19.9
18.4
—
7
30
(3013707) Erythrocyte sedimentation rate by Westergren method
15
99
2.22
1.08
5.0
3.5
mm/h
20.7
10.6
1.70
15
87
(42870588) Differential panel, method unspecified - Blood
8
42
2.30
1.01
13.4
4.3
—
—
—
0
0
(3015377) Calcium [Moles/volume] in Serum or Plasma
8
43
2.24
0.99
1.6
2.8
mmol/l
2.3
2.4
—
8
38
(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma
10
58
2.18
0.96
8.5
4.3
mmol/l
1.2
1.2
—
10
51
(3001122) Ferritin [Mass/volume] in Serum or Plasma
9
53
2.06
0.88
2.3
2.4
ug/l
279.8
121.1
—
9
48
(3019309) Folate [Moles/volume] in Red Blood Cells
6
33
2.06
0.85
1.2
1.6
nmol/l
1180.8
1257.0
—
6
24
(3026008) Bacteria identified in Urine by Culture
7
41
1.96
0.78
2.3
3.0
—
—
—
0
0
(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
8
50
1.86
0.70
1.9
2.2
nmol/l
70.6
76.7
—
8
45
(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting
10
139
0.54
0.68
4.0
4.0
mmol/l
1.7
1.3
—
10
127
(3044640) Blood type and Crossmatch panel - Blood
6
34
1.99
0.64
2.2
1.8
—
—
—
0
0
(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14
103
1.78
0.64
4.9
3.9
pmol/l
15.8
15.2
0.37
14
88
(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma
11
144
0.59
0.55
3.9
4.6
mmol/l
1.2
1.4
1.68
11
132
(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma
12
149
0.64
0.43
4.7
5.4
mmol/l
2.7
2.6
0.20
12
135
(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
15
123
1.52
0.38
13.8
5.7
u/l
124.5
77.2
0.87
15
113
(3044889) 12 lead EKG panel
13
104
1.50
0.36
3.5
4.1
—
—
—
0
0
(3019900) Cholesterol [Moles/volume] in Serum or Plasma
12
145
0.68
0.33
4.0
4.6
mmol/l
4.5
4.5
0.05
12
132
(40761511) CBC panel - Blood by Automated count
13
153
0.70
0.29
27.3
12.8
—
—
—
0
0
(3033658) Prothrombin time (PT) actual/Normal
5
36
1.48
0.26
4.2
2.9
%
94.8
92.1
—
5
36
(4010399)
0
10
0.00
0.22
0.0
1.3
—
—
—
0
0
(3004588) Protein electrophoresis panel - Serum or Plasma
0
10
0.00
0.22
0.0
1.4
—
—
—
0
0
(3037467) Urinalysis macro (dipstick) panel - Urine
8
93
0.80
0.17
3.8
4.5
—
—
—
0
0
(3012516) Albumin [Mass/volume] in Urine
5
42
1.23
0.11
1.4
3.3
mg/l
91.2
10.6
—
5
25
(3025839) Triglyceride [Moles/volume] in Serum or Plasma
5
43
1.20
0.11
2.4
1.8
mmol/l
2.2
1.7
—
5
36
(3015736) pH of Urine
5
45
1.14
0.10
2.6
3.2
—
—
—
0
0
(3009508) Creatinine [Moles/volume] in Urine
5
45
1.14
0.10
1.4
3.2
mmol/l
10.0
8.2
—
5
40
(3020682) Albumin/Creatinine [Ratio] in Urine
5
47
1.08
0.10
2.2
4.2
mg/mmol
6.0
1.7
—
5
25
(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
15
157
0.89
0.02
20.9
9.4
u/l
25.7
24.5
0.13
15
150
(3023103) Potassium [Moles/volume] in Serum or Plasma
15
156
0.91
0.01
26.1
14.2
mmol/l
4.0
4.0
0.07
15
151
(3004410) Hemoglobin A1c/Hemoglobin.total in Blood
13
136
0.91
0.01
5.6
5.8
mmol/mol
40.5
40.9
0.04
13
127
(3019550) Sodium [Moles/volume] in Serum or Plasma
15
154
0.94
0.00
26.4
14.4
mmol/l
139.7
139.9
0.17
15
148
(3020564) Creatinine [Moles/volume] in Serum or Plasma
15
154
0.94
0.00
28.9
15.4
umol/l
78.3
77.0
0.07
15
154
(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3000330) Specific gravity of Urine by Test strip
0
6
0.00
0.00
0.0
2.8
—
—
—
0
0
(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3039443) Prostate specific Ag panel - Serum or Plasma
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(3010421) pH of Blood
0
5
0.00
0.00
0.0
2.2
—
7.4
—
0
5
(40760888) Immunoglobulin light chains.free panel - Serum
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3045414) Leukocytes [Presence] in Urine
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
5
51
0.98
0.00
2.6
3.2
—
—
—
0
0
(21494755) Public health laboratory ask at order entry panel
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
6
67
0.86
0.00
3.8
3.0
—
—
—
0
0
(3021387) Prolactin [Units/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.8
—
323.4
—
0
5
(3016543) Leukocytes [#/volume] in Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.0
—
1.4
—
0
5
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3027315) Oxygen [Partial pressure] in Blood
0
5
0.00
0.00
0.0
1.8
—
7.8
—
0
5
(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
0
5
0.00
0.00
0.0
1.4
—
1.1
—
0
5
(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(3030981) Hyaline casts [#/volume] in Urine by Automated count
0
5
0.00
0.00
0.0
2.8
—
0.0
—
0
5
(3027475) Erythrocytes [#/volume] in Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.4
—
14.0
—
0
5
(3013290) Carbon dioxide [Partial pressure] in Blood
0
5
0.00
0.00
0.0
1.8
—
4.7
—
0
5
(3052851) Hemolysis interference index of Serum or Plasma
0
7
0.00
0.00
0.0
3.4
—
—
—
0
0
(3019473) Protein [Mass/volume] in Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.0
—
392.2
—
0
5
(3018251) Fasting glucose [Moles/volume] in Serum or Plasma
14
140
1.00
0.00
3.5
4.9
mmol/l
6.4
6.1
0.25
14
128
(3019832) Treponema pallidum Ab [Presence] in Serum
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint MYELOFIBROSIS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have MYELOFIBROSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: MYELOFIBROSIS – Myelofibrosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data